Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10901253 | 0.86 | CHRM1 (0.39) | CA2MAPK1 | |
| SCHEMBL29211085 | 0.82 | — | — | |
| SCHEMBL8580273 | 0.81 | GPR84 (0.42) | CA2MAPK1 | |
| SCHEMBL1782251 | 0.77 | — | — | |
| SCHEMBL5201370 | 0.75 | — | — | |
| SCHEMBL16085875 | 0.73 | GPR84 (0.37) | FFAR3 | |
| SCHEMBL29211106 | 0.73 | CHRM1 (0.41) | CA2MAPK1 | |
| SCHEMBL27386281 | 0.72 | CA2 (0.43) | CA2MAPK1 | |
| SCHEMBL29211129 | 0.70 | GPR84 (0.50) | — | |
| SCHEMBL8971531 | 0.69 | GPR84 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2014070092-A1 | FUNCTIONALIZED CELLULOSE NANOCRYSTALS, A METHOD FOR THE PREPARATION THEREOF AND USE OF FUNCTIONALIZED CELLULOSE NANOCRYSTALS IN COMPOSITES AND FOR GRAFTING | SWETREE TECHNOLOGIES AB (SE) | 2014-05-08 | — | — | WO | disclosed |
| EP-2513061-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. Lundbeck A/S (DK) | 2012-10-24 | — | — | EP | disclosed |
| US-8207347-B2 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2012-06-26 | — | — | US | disclosed |
| WO-2011072691-A1 | PYRIDONE DERIVATIVES AS NK3 ANTAGONISTS | H. LUNDBECK A/S (DK) | 2011-06-23 | — | — | WO | disclosed |
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | H. LUNDBECK A/S (DK) | 2011-06-16 | — | — | US | disclosed |
| EP-1388534-A2 | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | Allergan, Inc. (US) | 2004-02-11 | — | — | EP | disclosed |
| EP-1117628-B1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN INC (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-0986537-B1 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RES & DEV (FR) | 2002-08-07 | — | — | EP | disclosed |
| US-6403638-B1 | COMPOUND FOR USE IN TREATING SKIN DISEASES AND DISORDERS, AND FOR TREATING HYPERVITAMINOSIS A SYNDROME | ALLERGAN SALES, INC. | 2002-06-11 | — | — | US | disclosed |
| WO-2001070662-A2 | 2,4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN , INC. (US) | 2001-09-27 | — | — | WO | disclosed |
| EP-1117628-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | Allergan Sales, Inc. (US) | 2001-07-25 | — | — | EP | disclosed |
| US-6147224-A | 2,4-pentadienoic acid derivatives having selective activity for retinoid X (RXR) receptors | ALLERGAN SALES, INC. (US) | 2000-11-14 | — | — | US | disclosed |
| WO-2000020370-A1 | 2, 4-PENTADIENOIC ACID DERIVATIVES HAVING SELECTIVE ACTIVITY FOR RETINOID X (RXR) RECEPTORS | ALLERGAN SALES, INC. (US) | 2000-04-13 | — | — | WO | disclosed |
| EP-0986537-A2 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | Galderma Research & Development, S.N.C. (FR) | 2000-03-22 | — | — | EP | disclosed |
| WO-1999050239-A2 | NOVEL HETEROETHYNYLENE COMPOUNDS AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING SAME | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 1999-10-07 | — | — | WO | disclosed |
| US-4179561-A | REACTING A 3-DIAZOOXINDOLE WITH A SUBSTITUTED ACETYLENE | E. R. SQUIBB & SONS, INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4112096-A | ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1978-09-05 | — | — | US | disclosed |
| US-4076818-A | ANTIALLERGENS | E. R. SQUIBB & SONS, INC. (US) | 1978-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144164-A1 | Pyridone derivatives as NK3 antagonists | KCNK3, GRIK3, KCND3 | FFAR3 829/4885CA2 4511/4885MAPK1 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.